Misonix: Bioventus lines up another $500M acquisition - 5 details
One month after Bioventus announced its plan to acquire spine devicemaker Misonix in a $518 million deal, the orthobiologics company is lining up a reported $500 million purchase of Israeli medtech company Cartiheal.
Read full article »
President & CEO
Stavros G. Vizirgianakis
Misonix is a New York-based medical device company that designs, develops, manufactures, and markets invasive therapeutic ultrasonic equipment for tissue removal treatments.
Read more